Special ReportsAll NewsFDA BriefsOncology IconsThe Targeted PulseVoices from the Field
Conference CoverageConference ListingData Dialogue with the Oncology Brothers
All VideosCase-Based Peer PerspectivesEvolving Paradigms in OncologyExpert Perspective Virtual Tumor BoardInterviewsInvestigator PerspectivesMedical World NewsPersonalized MedicinePivotal Practice Views with the Oncology BrothersPodcastsSpeaking Out
All PublicationsEvolving ParadigmsPeers & Perspectives in OncologyTargeted Therapies in Oncology
CASE-BASED ROUNDTABLEPARTNERS
CME/CEClinical TrialsEventsPrecision Medicine PerspectivesPress ReleasesSponsored ContentTreatment Resources
SUBSCRIBE
BRAIN CANCER
BREAST CANCERBREAST CANCER
GENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERS
GENOMIC TESTINGGENOMIC TESTING
GI CANCERSGI CANCERSGI CANCERSGI CANCERSGI CANCERS
GYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERS
HEAD & NECK CANCERS
HEMATOLOGYHEMATOLOGY
IMMUNOTHERAPYIMMUNOTHERAPY
LEUKEMIASLEUKEMIASLEUKEMIASLEUKEMIAS
LUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCER
LYMPHOMASLYMPHOMASLYMPHOMASLYMPHOMAS
MPNs
MULTIPLE MYELOMA
NTRK GENE FUSIONS
SARCOMA
SKIN CANCERSSKIN CANCERS
THYROID CANCERS
Spotlight -
  • Myeloma
  • Chronic Lymphocytic Leukemia
  • Gynecologic Cancers
  • Genomic Testing
  • Melanoma
  • Genitourinary Cancers
BRAIN CANCER
BREAST CANCERBREAST CANCER
GENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERS
GENOMIC TESTINGGENOMIC TESTING
GI CANCERSGI CANCERSGI CANCERSGI CANCERSGI CANCERS
GYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERS
HEAD & NECK CANCERS
HEMATOLOGYHEMATOLOGY
IMMUNOTHERAPYIMMUNOTHERAPY
LEUKEMIASLEUKEMIASLEUKEMIASLEUKEMIAS
LUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCER
LYMPHOMASLYMPHOMASLYMPHOMASLYMPHOMAS
MPNs
MULTIPLE MYELOMA
NTRK GENE FUSIONS
SARCOMA
SKIN CANCERSSKIN CANCERS
THYROID CANCERS
    • CASE-BASED ROUNDTABLE
    • PARTNERS
    • SUBSCRIBE

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

Trending News on Targeted Oncology, Week of November 6, 2020

November 6, 2020
By Danielle Ternyila
Article

A review of the trending news in oncology online for the week of November 6, 2020, including recent news from the FDA on the cancer treatment paradigm, updates in oncology, and the latest information regarding COVID-19.

This week, the FDA lifted a partial clinical hold on the phase 1 P-PSMA-101-001 clinical trial (NCT04249947), which is exploring chimeric antigen receptor (CAR) T product as a potential treatment for patients with metastatic castration-resistant prostate cancer.

It is a busy time of year for medical conferences, and Targeted Oncology is covering the latest updates this week from the latest meetings, including 38th Annual Chemotherapy Foundation Symposium on November 4-6, 2020, the 2020 International Kidney Cancer Symposium on November 6-7, and the 15th Annual New York Lung Cancers Symposium on November 7, 2020.

These updates and others were trending:

Phase 2 Study Examines Validity of Novel Nivolumab/Ipilimumab Strategy in Advanced RCC

Based on results from the phase 2 OMNIVORE study, the response-based strategy achieved no complete responses and a low partial response/complete response conversion in advanced renal cell carcinoma.

Heymach Discusses MET Exon 14 Skipping Mutations in NSCLC

During a Targeted Oncology Case Based Peer Perspective event, John V. Heymach, MD, PhD, of the The University of Texas MD Anderson Cancer Center, discussed the testing methods for non–small cell lung cancer (NSCLC) with MET exon 14 skipping mutations. The discussion was based on the case of a 48-year-old woman.

Greater Diversity of Cancer Models May Help Combat “Imprecision” in Personalized Care

A greater understanding of genomic characteristics of racial and ethnic minority populations with cancer are necessary to further advance therapy development and lead to successful treatment for all patients.

HER2-Positive Breast Cancer Treatment Landscape Expands With Promise of New Therapies

In an interview with Targeted Oncology, William J. Gradishar, MD, of Northwestern University's Feinberg School of Medicine, discussed the current treatment options for patients with HER2-positive breast cancer, including the recently approved therapies from the FDA.

Disease Progression More Likely in African American Men With Prostate Cancer, Study Shows

A statistically significant increase in the 10-year cumulative incidence of disease progression and definitive treatment among African American men compared with non-Hispanic Caucasian men with low-risk prostate cancer, according to findings from a retrospective cohort study.

Cabozantinib Plus Nivolumab Improves Efficacy Over Sunitinib in mRCC

Ulka Vaishampayan, MD, of Barbara Ann Karmanos Cancer Institute, discusses the findings from the phase 3 CheckMate-9ER study, which demonstrated promising response and survival outcomes with the combination of cabozantinib (Cabometyx) plus nivolumab (Opdivo) as treatment of patients with metastatic renal cell carcinoma compared with sunitinib.

The Ongoing Fight Against Acute GvHD​

John F. DiPersio, MD, PhD, of Washington University School of Medicine, provides insight into recent data updates from ongoing trials studying the management of graft-versus-host disease with promising regimens.

Special Feature: COVID-19

Leronlimab Appears to Prevent Progression to Severe or Critical COVID-19

Findings from the phase 2 CD10 study of leronlimab (PRO 140) as treatment of patients with mild-to-moderate coronavirus disease 2019 (COVID-19) suggest the agent can prevent progression to severe or critical disease.

As the COVID-19 Pandemic Continues, Fewer Patient-Physician Encounters Suggest Later-Stage Disease at Presentation

A report demonstrated the potential impact of COVID-19 on cancer-related patient encounters, which may result in an increase in the presentation of later-stage disease for newly diagnosed patients in future months.

Newsletter

Stay up to date on practice-changing data in community practice.

Subscribe Now!
Recent Videos
Related Content

Across Cancer Types, Trispecific Antibodies Show Promise in Early Result

Across Cancer Types, Trispecific Antibodies Show Promise in Early Result

Tony Berberabe, MPH
July 16th 2025
Article

Innovative trispecific antibodies show promise in treating relapsed/refractory multiple myeloma and neuroendocrine carcinoma, enhancing patient outcomes and safety.

Read More


Predicting Palbociclib Outcomes in Breast Cancer Using Deep Learning

Predicting Palbociclib Outcomes in Breast Cancer Using Deep Learning

Jordyn Sava;Xiaojie Zhang, MD;Akshat Singhal, PhD
April 15th 2025
Podcast

Xiaojie Zhang, MD, and Akshat Singhal, PhD, discuss their research leveraging deep learning to predict how patients with ER+/HER2- breast cancer will respond to palbociclib.

Listen


Awareness of TIL Therapy for Melanoma Is Crucial for Timely Referral

Awareness of TIL Therapy for Melanoma Is Crucial for Timely Referral

Targeted Oncology Staff
July 15th 2025
Article

During a live event, Barbara T. Ma, MD, MS, reviewed guidelines on management and best practices for the use of tumor-infiltrating lymphocytes in melanoma.

Read More


BMT CTN 1902 in Myeloma: Key Findings With Garfall

BMT CTN 1902 in Myeloma: Key Findings With Garfall

Jordyn Sava;Alfred L. Garfall, MD, MS
March 13th 2025
Podcast

In this episode of Targeted Talks, Alfred L. Garfall, discusses the phase 2 BMT CTN 1902 trial of idecabtagene vicleucel in patients with multiple myeloma.

Listen


Immunotherapy Duo Shows 42% 2-Year Survival in MSS CRC Trial

Immunotherapy Duo Shows 42% 2-Year Survival in MSS CRC Trial

Sabrina Serani
July 15th 2025
Article

Agenus reveals promising survival rates for its immunotherapy in metastatic colorectal cancer, potentially transforming treatment for resistant patients.

Read More


FDA Grants Orphan Drug Designation to SH-110, a Liquid Glioma Therapy

FDA Grants Orphan Drug Designation to SH-110, a Liquid Glioma Therapy

Jordyn Sava
July 15th 2025
Article

The FDA designates SH-110 as an orphan drug, offering a safer oral treatment option for glioma patients with swallowing difficulties.

Read More

Related Content

Across Cancer Types, Trispecific Antibodies Show Promise in Early Result

Across Cancer Types, Trispecific Antibodies Show Promise in Early Result

Tony Berberabe, MPH
July 16th 2025
Article

Innovative trispecific antibodies show promise in treating relapsed/refractory multiple myeloma and neuroendocrine carcinoma, enhancing patient outcomes and safety.

Read More


Predicting Palbociclib Outcomes in Breast Cancer Using Deep Learning

Predicting Palbociclib Outcomes in Breast Cancer Using Deep Learning

Jordyn Sava;Xiaojie Zhang, MD;Akshat Singhal, PhD
April 15th 2025
Podcast

Xiaojie Zhang, MD, and Akshat Singhal, PhD, discuss their research leveraging deep learning to predict how patients with ER+/HER2- breast cancer will respond to palbociclib.

Listen


Awareness of TIL Therapy for Melanoma Is Crucial for Timely Referral

Awareness of TIL Therapy for Melanoma Is Crucial for Timely Referral

Targeted Oncology Staff
July 15th 2025
Article

During a live event, Barbara T. Ma, MD, MS, reviewed guidelines on management and best practices for the use of tumor-infiltrating lymphocytes in melanoma.

Read More


BMT CTN 1902 in Myeloma: Key Findings With Garfall

BMT CTN 1902 in Myeloma: Key Findings With Garfall

Jordyn Sava;Alfred L. Garfall, MD, MS
March 13th 2025
Podcast

In this episode of Targeted Talks, Alfred L. Garfall, discusses the phase 2 BMT CTN 1902 trial of idecabtagene vicleucel in patients with multiple myeloma.

Listen


Immunotherapy Duo Shows 42% 2-Year Survival in MSS CRC Trial

Immunotherapy Duo Shows 42% 2-Year Survival in MSS CRC Trial

Sabrina Serani
July 15th 2025
Article

Agenus reveals promising survival rates for its immunotherapy in metastatic colorectal cancer, potentially transforming treatment for resistant patients.

Read More


FDA Grants Orphan Drug Designation to SH-110, a Liquid Glioma Therapy

FDA Grants Orphan Drug Designation to SH-110, a Liquid Glioma Therapy

Jordyn Sava
July 15th 2025
Article

The FDA designates SH-110 as an orphan drug, offering a safer oral treatment option for glioma patients with swallowing difficulties.

Read More

About Us
Advertise
Contact Us
CureToday.com
CancerNetwork.com
OncLive.com
OncNursingNews.com
Do Not Sell My Information
Privacy
Terms & Conditions
Editorial Board
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.